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Therapies that can selectively target the tumour vasculature
represent an attractive approach to limiting the growth of tumours.
5,6-Dimethylxanthenone-4-acetic acid (DMXAA, Figure 1),
synthesized in this laboratory, demonstrates excellent activity
against murine tumours, inducing irreversible cessation of tumour
blood flow within 4 h of administration with little effect on
perfusion of normal tissues (Zwi et al, 1994; Lash et al, 1998).
The ischaemia and haemorrhagic necrosis that follow provide a
histological appearance similar to that of tumours treated with
tumour necrosis factor-a (TNF-a) (Zwi et al, 1994). DMXAA
elevates serum TNF-a activity in a manner that correlates with the
anti-tumour response (Philpott et al, 1995), suggesting that the
induction of TNF-a plays an essential role in its anti-tumour
action. The anti-tumour activity and tumour blood flow effects
of flavone acetic acid (FAA), a compound closely related to
DMXAA, is inhibitable by antibodies to TNF-a (Mahadevan et al,
1990; Pratesi et al, 1990), further supporting this hypothesis.
In murine systems, FAA and DMXAA exhibit similar profiles
of immune modulation, cytokine induction and anti-tumour activi-
ties, with the exception that DMXAA is 12-fold more potent than
FAA (Ching et al, 1991; Rewcastle et al, 1991). However, only
DMXAA up-regulates TNF-a mRNA in human cell lines (Ching
et al, 1994a; Patel et al, 1997), and induces TNF-a production in
cultured human peripheral blood cells (Philpott et al, 1997). Thus,
DMXAA appears to be a superior clinical candidate to FAA in that
it is more dose-potent and does not exhibit the mouse-human
species preference of FAA. DMXAA is currently undergoing
phase I clinical trial as a single agent.
Thalidomide, a small molecule with diverse pharmacological
and biological effects, selectively inhibits TNF-a synthesis
induced by lipopolysaccharide (LPS) (Moreira et al, 1993) and
DMXAA (Ching et al, 1995). Thalidomide has attracted much
interest in the treatment of leprosy (Sheskin, 1965; Sampaio et al,
1991), Behçet’s disease (Gardner-Medwin et al, 1994) and pruritus
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Summary 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), synthesized in this laboratory and currently in phase I clinical trial, is a low
molecular weight inducer of tumour necrosis factor-a (TNF-a). Administration of DMXAA to mice with established transplantable tumours
elicits rapid vascular collapse selectively in the tumour, followed by extensive haemorrhagic necrosis mediated primarily through the
production of TNF-a. In this report we have investigated the synthesis of TNF-a mRNA in hepatic, splenic and tumour tissue. Co-
administration of thalidomide with DMXAA increased anti-tumour activity and increased intra-tumoural TNF-a production approximately
tenfold over that obtained with DMXAA alone. Thalidomide increased splenic TNF-a production slightly but significantly decreased serum and
hepatic levels of TNF-a induced with DMXAA. Lipopolysaccharide (LPS) induced 300-fold higher serum TNF-a than did DMXAA at the
maximum tolerated dose, but induced similar amounts of TNF-a in spleen, liver and tumour. Splenic TNF-a activity induced with LPS was
slightly increased with thalidomide, but serum and liver TNF-a levels were suppressed. Thalidomide did not increase intra-tumoural TNF-a
production induced with LPS, in sharp contrast to that obtained with DMXAA. While thalidomide improved the anti-tumour response to
DMXAA, it had no effect on the anti-tumour action of LPS that did not induce a significant growth delay or cures against the Colon 38 tumour.
The increase in the anti-tumour action by thalidomide in combination with DMXAA corresponded to an increase in intra-tumoural TNF-a
production. Co-administration of thalidomide may represent a novel approach to improving selective intra-tumoural TNF-a production and
anti-tumour efficacy of DMXAA.
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O(Silva et al, 1994), but was withdrawn from use as a sedative and
anti-emetic in the 1960s because of its teratogenicity (Fabro et al,
1967). Recent studies indicate that its immunosuppressive and
anti-inflammatory effects would be beneficial to the treatment of
graft-versus-host disease (Vogelsang et al, 1992; Uthoff et al,
1995), rheumatoid arthritis (Gutierrez-Rodriguez et al, 1989),
prevention of graft rejection (Vogelsang et al, 1988; Uthoff et al,
1995), HIV/AIDS (Makonkawkeyoon et al, 1993; Moreira et al,
1997), sarcoidosis (Carlesimo et al, 1995) and various other
inflammatory diseases (Burroughs et al, 1995).
In experiments to determine whether suppression of serum
TNF-aproduction by thalidomide affected the antitumour
response to DMXAA, we found that, while serum TNF-alevels
decreased, anti-tumour activity was unexpectedly improved
(Ching et al, 1995). Reduction of tumour blood flow induced by
DMXAA, which is thought to be mediated by TNF-a, was not
reversed by thalidomide (Browne et al, 1998). Thalidomide
analogues that were more potent than thalidomide in inhibiting
DMXAA-induced serum TNF-awere also more potent in
improving the anti-tumour response, indicating that the two
activities were associated (Ching et al, 1998). Pentoxifylline,
another inhibitor of TNF-asynthesis differing from thalidomide in
both structure and mechanism of inhibition (Han et al, 1990;
Moreira et al, 1993), also increased the anti-tumour action of
DMXAA (Ching et al, 1998).
Results with LPS also raise questions about the relationship
between TNF-aproduction and anti-tumour effect. While LPS is
more effective than DMXAA as an inducer of serum TNF-a, and
both induce haemorrhagic necrosis of Colon 38 tumours, only
DMXAA induces long tumour growth delays and cures (Ching
et al, 1994b). In this report, we consider whether TNF-apro-
duction in tissues, rather than in serum, provides an explanation
of anti-tumour effects. We have combined the results of several
techniques to investigate the effects of DMXAA and LPS in
combination with thalidomide.
MATERIALS AND METHODS
Mice
C57B1/6 mice were purchased from the Department of Laboratory
Animal Science, Otago Medical School, Dunedin, New Zealand.
(C57B1/6 3DBA/2)F1 hybrid mice were bred in our animal
facility and were housed under conditions of constant temperature
and humidity according to institutional ethical guidelines. All mice
were used between 8 and 12 weeks of age.
Materials
DMXAA, synthesized in this laboratory (Rewcastle et al, 1991),
was dissolved in 5% sodium bicarbonate and injected in a volume
of 0.01ml g21 body weight. (C57B1/6 3DBA/2)F1 mice and
C57B1/6 mice were treated with DMXAA at their respective
optimal therapeutic dose of 30mg kg21 and 22.5mg kg21. LPS
(Escherichia coliserotype 055:B5, purchased from Sigma) was
dissolved in water and injected at its maximum tolerated dose of
175mg per 0.2ml per mouse (Ching et al, 1995). (2)-Thalidomide
was synthesized in this laboratory according to published methods
(Casini and Ferappi, 1964), dissolved in dimethyl sulphoxide and
injected at 2.5ml g21 at a dose of 100mg kg21.
Tumour growth inhibition assays
(C57B1/6 3DBA/2)F1 mice were implanted under anaesthesia
(sodium pentobarbital, 90mg kg21) subcutaneously in the left
flank with Colon 38 tumour fragments. When the tumours were
approximately 4mm in diameter (generally 7–9 days after implan-
tation), mice were treated intraperitoneally with drug. Tumours
were measured thrice weekly after treatment and tumour volumes
were calculated as 0.52 a2 3b, where a and b are the minor and
major axes of the tumour. The arithmetic means and standard
errors were calculated for each point, including animals having
zero measured tumour volume, and expressed as a fraction of the
pretreatment volume. Growth delay was determined as the differ-
ence in the number of days required for the untreated, control and
treated tumours to reach four times the pretreatment volume. Six
mice were used for each group, and mice in which the tumour had
completely disappeared were kept for at least 3 months to ensure
that the tumours did not re-grow.
In situ hybridization
C57B1/6 mice with tumours approximately 6mm in diameter
were treated with DMXAA (22.5mg kg21), or LPS (175mg per
mouse) and, after 4h, asphyxiated with nitrogen, and tissues fixed
by whole body perfusion of paraformaldehyde in borate buffer.
Tissues were further fixed after removal, snap-frozen in isopentane
in liquid nitrogen, and cryosections (15mM) were cut. The
mounted sections were further fixed with paraformaldehyde,
deproteinized using proteinase K, equilibrated in triethanolamine
to block positive charges, and dehydrated with ascending concen-
trations of ethanol. 33P-labelled antisense riboprobe (2 3107 cpm
ml21) in hybridization buffer (50% formamide, 0.2Msodium chlo-
ride, 1 3Denhardt’s solution, 1mM EDTA, 2mMTris–HCl, 0.1%
dextran sulphate, 0.1mg ml21 tRNA, 2mMdithiothreitol) was
overlaid on the sections, cover-slipped and sealed, and hybridized
overnight at 658C. After hybridization, the sections were digested
with RNAase (10mg ml21, 30min at 378C), washed twice
(5min) with 2 3standard saline citrate (SSC), once (10min) with
1 3SSC, and once (10min) with 0.5 3SSC, all at room tempera-
ture. Final high stringency washes were carried out using
0.1 3SSC for 30min at 658C, followed by a final wash with
0.1 3SSC (5min at room temperature). Sections were dehydrated
through ethanol plus 1 3SSC, air-dried and processed for auto-
radiography. After 2–3 weeks the slides were developed and
stained with haematoxylin and eosin. Sections of tissues from
untreated mice were processed in an identical manner. The anti-
sense murine TNF-ariboprobe was transcribed from a cDNA
template encoding 700 base pairs of the murine TNF-agene.
Probes were radiolabelled using 33P-UTP and a Riboprobe Gemini
II labelling kit from Promega.
Northern analysis
Organs were excised from sacrificed mice, minced using scalpel
blades, and total cellular RNA was extracted using Trizol (Gibco
BRL) according to manufacturer’s instructions. The RNA samples
(10mg) were fractionated by electrophoresis on a formaldehyde-
denaturing 1% agarose gel and transferred overnight to a nylon
membrane (Hybond N1, Amersham). After UV cross-linking (120
mJoule, UV-Stratalinker, Stratagene, San Diego, CA, USA), the
membrane was baked (30min, 788C), and each membrane was
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pre-hybridized (2 h, 428C) in 7 ml hybridization mix (50%
formamide, 0.075 M sodium chloride, 0.05 M sodium dihydrogen
phosphate, 5 mM EDTA, 0.001% polyvinyl pyrrolidone, 0.001%
bovine serum albumin, 0.001% Ficoll, 0.01 mg ml21 herring sperm
DNA and 0.5% sodium dodecyl sulphate (SDS)). The cDNA to
murine TNF-a mRNA was labelled with a32P-dCTP (Amersham)
using a random priming kit (RTS Radprime DNA labelling
system, Gibco BRL). Excess radioactivity was removed by elution
through a G-50 Sephadex column and labelled probe (106 cpm
ml21 hybridization mix) was then added to the membrane and
hybridized for 36 h at 428C. The blots were washed twice in
2 3 SSC with 0.1% SDS for 10 min at 428C, and finally in
0.2  3 SSC with 0.1% SDS for 10 min at 658C. Blots were exposed
to X-ray film for 1–3 days at 2708C. Membranes were then
stripped (two washes in 300 ml 0.1 3 SSC with 1% SDS for
15 min at 808C) and re-hybridized with probe for human b-actin to
determine loading of the lanes. Intensity of signals was quantitated
by laser densitometric scanning.
TNF-a determination
Blood was collected from the ocular sinus from mice anaesthetized
with halothane, coagulated overnight at 48C then centrifuged for
30 min at 2000 g at 48C. Extractable TNF-a in spleen, liver and
tumour was measured using a previously published method (Yang
et al, 1994). Tissues were excised, weighed and homogenized in
a-modified minimal essential medium (2 ml) using a tissue
homogenizer. Homogenates were centrifuged at 2000 g for 30 min
at 48C, and the supernatant was removed and centrifuged at
14 000 g for 30 min at 48C before assay. TNF-a activity was
measured using the standard L929 cytotoxicity assay (Hogan and
Vogel, 1990; Philpott et al, 1995). L929 cells (3 3 104 per well)
were allowed to adhere overnight to the bottom of flat-bottomed
96-well plates. The cells were then sensitized with Actinomycin D
(8 mg ml21 final concentration) for 1 h before the addition of serial
dilutions of the samples to be assayed. Cell killing was assessed
after 24 h by a colourimetric assay using 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide as previously
described (Philpott et al, 1995). One unit of TNF-a was defined
as that required to produce 50% killing of L929 cells.
RESULTS
Comparative effects of thalidomide on the anti-tumour
action of DMXAA and LPS
We first investigated whether thalidomide could improve the
anti-tumour action of LPS, another inducer of TNF-a, as it does
with DMXAA (Ching et al, 1995). As shown in Figure 2, thalido-
mide did not improve the response to LPS; rather the tumours in
the groups receiving thalidomide only or in combination with LPS
grew at a slightly faster rate than the untreated tumours. LPS
induced a growth delay of 3 days, and one of the mice in the group
of six was cured. By comparison, DMXAA alone induced a
growth delay of 17 days and a cure rate of 83%, and in combina-
tion with thalidomide, all the mice were cured.
Effect of thalidomide on TNF-a mRNA and protein
production induced by DMXAA or LPS
C57B1/6 mice with Colon 38 tumours were treated with DMXAA
(22.5 mg kg21) or LPS (175 mg per mouse), with or without
thalidomide (100 mg kg21). Mice were bled, and spleen, liver and
tumours excised 1–5 h after treatment. Serum was prepared from
the blood samples for TNF-a measurements and organs were
analysed for both TNF-a mRNA using Northern blots, and for
TNF-a activity using a bioassay. DMXAA up-regulated TNF-a
mRNA in spleen, liver and tumour within 1 h, with maximal
activity at 2 h and declining thereafter. Co-administration of
thalidomide resulted in a sustained and heightened transcription of
TNF-a mRNA in the spleen and tumour, with TNF-a mRNA
elevated to 5 h after treatment (Figure 3A). In the liver, thalido-
mide suppressed transcription as well as delaying the peak to 4 h
(Figure 3A). LPS also up-regulated TNF-a mRNA in spleen, liver
and tumour, and thalidomide suppressed transcription in all three
tissues with no apparent alteration of the kinetics (Figure 3B).
Thalidomide alone did not induce TNF-a mRNA in any of the
tissues at 2 h (Figure 3 A, B).
DMXAA and LPS induced TNF-a protein, as measured by
bioassay, in the serum, spleen, liver and tumour (Figure 4). LPS
Figure 2 Effect of thalidomide on the anti-tumour action of DMXAA (A) and
LPS (B). Results for DMXAA are redrawn from a previously published study
(Ching et al, 1995) to allow comparison. (C57B1/6 3 DBA/2)F1 mice with
Colon 38 tumours were treated with drugs and the growth of tumours
followed. Untreated tumours, (•); thalidomide (100 mg kg21 alone (n);
DMXAA (30 mg kg21 or LPS (175 mg per mouse) alone (s) or in combination
with thalidomide (t). Six mice per group
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induced 300-fold higher amounts of serum TNF-a than DMXAA
with a peak 1 h after administration. Tissue TNF-a activity was
high 1 h after LPS administration and it is possible that some of
the measured TNF-a activity derived from contaminating blood
since tissues were not perfused before extraction. The differential
effects of thalidomide on TNF-a activity were in general more
pronounced than those observed for TNF-a mRNA (Figure 4). In
serum, spleen and liver, thalidomide delayed peak TNF-a activity
following DMXAA from 2 h to 4 h and suppressed peak activity
in serum and liver. TNF-a activity in the tumour increased with
time after DMXAA treatment and peak activity was dramatically
increased (ninefold) by thalidomide co-administration (Figure 4).
In the case of LPS, thalidomide suppressed TNF-a responses in
serum, spleen and tumour, and delayed the peak activity by 1–2 h.
Thalidomide slightly increased TNF-a activity in the spleen.
Effect of thalidomide on the number of cells in the
tumour expressing TNF-a mRNA after DMXAA
The increased TNF-a mRNA in tumour tissue caused by co-
administration of thalidomide with DMXAA (Figure 4) could
result from either increased transcription or an increased pro-
portion of responding cells. Sections of tumour were therefore
taken 4 h after treatment from mice treated with DMXAA (22.5
mg kg21) with or without thalidomide (100 mg kg21), and cells
expressing TNF-a mRNA were identified by in situ hybridization
to an antisense riboprobe for TNF-a. Tumour tissue from control
animals and from animals treated with thalidomide alone showed
no labelling of cells. Tumour tissue from mice treated with
DMXAA with or without thalidomide were both heavily labelled,
but the number of labelled cells was similar (Figure 5).
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Figure 3 Effect of thalidomide on TNF-a mRNA up-regulation induced with DMXAA (A) and LPS (B). C57B1/6 mice with Colon 38 tumours were treated with
DMXAA (22.5 mg kg21) or LPS (175 mg per mouse) alone or in combination with thalidomide (100 mg kg21). Tissues were excised after the times indicated and
processed for Northern blot analysis of TNF-a mRNA expression. Negative controls were from untreated mice (Untr) or from mice 2 h after receiving
thalidomide only (Thal). Tissues were pooled from three mice per group. The intensity of signals was quantitated, normalized by comparison with the signal for
human b-actin to determine loading of the lanes, and expressed as a bar graph720 Z Cao et al
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DISCUSSION
We have investigated differences in TNF-a production in the
tumour and systemic organs induced with LPS or DMXAA, with
or without thalidomide, to obtain an explanation for why thalido-
mide, which suppresses the serum TNF-a response to both LPS
and DMXAA, potentiates the anti-tumour activity only of
DMXAA. Thalidomide increases the peak intra-tumoural TNF-a
levels induced with DMXAA approximately tenfold while
decreasing LPS-induced tumour TNF-a by sixfold. It also
suppresses liver and serum TNF-a activity induced by LPS and
DMXAA, while slightly elevating splenic TNF-a production.
Thalidomide also delays the kinetics of TNF-a production from a
peak in the normal tissues at 2 h to 4 h after DMXAA treatment,
and from 1 h to 2 h after LPS (Figure 4).
The TNF-a activity in tumour tissue induced after 1 h by LPS is
much higher than that induced by DMXAA (Figure 4), demon-
strating that tumour-associated TNF-a per se does not correlate
with anti-tumour effect. Early (1–2 h) TNF-a synthesis may be
related to the induction of tumour haemorrhagic necrosis, which is
common to the action of both LPS and DMXAA (Ching et al,
1994b). On the other hand, the destruction of all tumour cells
required for tumour regression may require the presence of
tumour-associated TNF-a over a longer time period, as seen with
DMXAA. Examination of tumours treated with a sub-therapeutic
dose of DMXAA shows that co-administration of thalidomide
decreases surviving tumour cells (Ching et al, 1998), consistent
with this hypothesis. The results of Northern analysis (Figure 2),
combined with the in situ hybridization data (Figure 5), show that
co-administration of thalidomide with DMXAA does not increase
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the number of cells expressing TNF-a mRNA. Rather, elevation
of intra-tumoural TNF-a activity appears to be post-transcrip-
tional, accentuated by TNF-a entrapment following vascular
collapse.
The reason for the dramatic contrast in the effect of thalidomide
on intra-tumoural TNF-a activity induced with LPS or DMXAA is
not clear. In the tumour, DMXAA and LPS may activate different
cell populations. We have obtained evidence that DMXAA acti-
vates a broader range of cells than LPS and induces the tumour
cells themselves to produce TNF-a (Joseph et al, 1999). The
activity of LPS would be expected to be limited to cells such as the
host macrophages that express surface receptors that bind to it.
Moreover, different cell types may be differently regulated by
thalidomide. Thalidomide is noted for its inhibition of TNF-a
production by LPS-activated human blood monocytes in culture
(Sampaio et al, 1991), but bi-directional dose-dependent TNF-a
modulation has been reported, depending on the cell type and
stimulator used. Thalidomide enhanced TNF-a synthesis by the
HL-60 human leukaemia cell line induced with phorbol esters, but
inhibited TNF-a synthesis induced with okadaic acid in the same
cell line (Miyachi et al, 1996). While thalidomide inhibited
synthesis of TNF-a in LPS-stimulated cultures of unfractionated
human blood mononuclear cells, it enhanced TNF-a synthesis in
cultures of THP-1 cells and in the adherent population of human
blood mononuclear cells (Shannon and Sandoval, 1996).
The mechanism by which thalidomide modulates TNF-a
production is still unclear. Thalidomide selectively enhanced the
degradation of TNF-a mRNA (Moreira et al, 1993), but later work
suggests that thalidomide inhibits HIV replication in macrophages
through decreased binding activity of NFkB (Moreira et al, 1997),
an important transcription factor controlling activation of the
TNF-a gene (Shakov et al, 1990). As shown by photoaffinity-
labelled thalidomide, thalidomide binds to a1-acid glycoproteins
that have intrinsic anti-TNF-a activity (Turk et al, 1996).
In addition to regulating TNF-a synthesis, thalidomide has a
number of other effects that could contribute to the anti-tumour
response, including modulation of T lymphocytes, alteration of
pharmacokinetics and metabolism, and inhibition of angiogenesis.
The anti-tumour action of DMXAA against the Colon 38 tumour
is more efficient in immunocompetent hosts, indicating that host
T-cell immunity is beneficial to tumour regression (Ching et al,
1992). Although alterations to T-cell subsets by thalidomide were
not observed in one study (Shannon et al, 1994), co-stimulation of
purified primary human T lymphocytes was shown in another
(Haslett et al, 1998). We are actively investigating the effects of
thalidomide on the pharmacokinetics of DMXAA. Thalidomide
inhibits angiogenesis (D’Amato et al, 1994), and combination of
angiogenesis antagonists with conventional anticancer agents can
improve anti-tumour activity (Teicher et al, 1992). However, inhi-
bition of angiogenesis by thalidomide generally requires repeated
A B
C D
Figure 5 In situ hybridization, using an antisense probe for TNF-a, of Colon 38 tumour sections taken from C57B1/6 mice that were either untreated (A),
treated 4 h previously with DMXAA alone (22.5 mg kg21) (B), treated 4 h previously with thalidomide alone (100 mg kg21) (C), or treated 4 h previously with
DMXAA in combination with thalidomide (D)administration and we have not observed any action of thalido-
mide, given either as single or multiple injections, on the growth
of Colon 38 tumours (Ching et al, 1998).
In conclusion, our results, together with those from studies on
thalidomide analogues (Ching et al, 1998), strongly suggest that
modulation of the magnitude and kinetics of intra-tumoural
TNF-a production by thalidomide is the basis for its enhancement
of the anti-tumour action of DMXAA. Thalidomide, because of its
ability to increase anti-tumour efficacy whilst reducing serum
TNF-a activity, might be considered as an adjunct to DMXAA in
future clinical trials.
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